iiinova — where your digital self keeps evolving

TomasPascualMD

@tomaspascualmd.bsky.social

TomasPascualMD @tomaspascualmd.bsky.social · 26/03/2026

Great discussion at #EBCC15 on actionable targets beyond HER2 in breast cancer. We’re clearly moving toward a multi-biomarker-driven treatment strategy.

000

Reposted by TomasPascualMD

Elisabetta Bonzano MD, PhD @elisabettabonzano.bsky.social · 25/03/2026

📌Advances in targeted therapies ✨Beyond Her2+ ✨ led by @tomaspascualmd.bsky.social #EBCC15 @oncoalert.bsky.social #OncoAlertAF

121

Reposted by TomasPascualMD

SOLTI Cancer Research @soltiresearch.bsky.social · 18/02/2026

Nuevo artículo publicado en Nature Communications sobre el estudio PROMETEO (SOLTI-1503): lnkd.in/edCGqhaz 👨‍🔬 Primer autor del trabajo: Dr. Tomás Pascual 👨‍🔬 Investigador senior: Dr. Aleix Prat

101

TomasPascualMD @tomaspascualmd.bsky.social · 27/12/2025

Feliz Navidad!

000

Reposted by TomasPascualMD

SOLTI Cancer Research @soltiresearch.bsky.social · 22/12/2025

✅ The wait is over: BITES 6 is LIVE: "HER2-Positive breast cancer: updates on biomarkers and treatment strategies from 2025 onward". 🔗 www.scientificbites.com/register/us…

111

Reposted by TomasPascualMD

SOLTI Cancer Research @soltiresearch.bsky.social · 18/12/2025

Fueron muchos los momentos y las personas que nos ayudaron a escribir, por primera vez, la historia de SOLTI. 30 años concentrados en 45 minutos y un lema “Si SOLTI dice ven”. Descubre una historia llena de ciencia, valentía y emoción 🎬🧬✨ 🔗 youtu.be/PSvsFldXunU?si=_-QQ7PZhA5B… #beSOLTI

001

Reposted by TomasPascualMD

SOLTI Cancer Research @soltiresearch.bsky.social · 13/12/2025

SOLTI team is leaving #SABCS25 full of new ideas, insights, and renewed energy to keep advancing breast cancer research. A huge thank you to all the organizers, speakers, and colleagues. 📸 Here we are, celebrating a week full of learning, and shared knowledge! See you in 2026 🙌 #beSOLTI

001

Reposted by TomasPascualMD

SOLTI Cancer Research @soltiresearch.bsky.social · 15/12/2025

¿Sabías que tus pacientes pueden acceder al estudio HOPE-Focus para realizar un análisis de sangre y tejido tumoral y así obtener información molecular detallada? 👉 Más info y formulario de inscripción en 🔗 www.hopefocus.es #beSOLTI #HOPEFocus #cáncerdemama

001

TomasPascualMD @tomaspascualmd.bsky.social · 09/11/2025

Looking forward to participating in the @aseica.bsky.social - ASPIC Meeting, where I’ll be discussing the role of oncolytic viruses in immune activation in breast cancer. Grateful for the invitation and the opportunity to exchange ideas with such an outstanding scientific community.

011

Reposted by TomasPascualMD

Daniel Stover, MD, FASCO @stoverlab.bsky.social · 21/12/2024

Analysis of residual disease specimens is challenging - but a fascinating study pooling 4 HER2+ clinical trials! @oncoalert.bsky.social @tomaspascualmd.bsky.social www.sciencedirect.com/science/arti...

sciencedirect.com

Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC)

In HER2+ early breast cancer (EBC), we investigated tumor and immune changes during neoadjuvant treatment and their impact on residual disease (RD) bi…

0185